- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Septerna, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Septerna, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 27.03. | Septerna, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.03. | Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently | 2 | Insider Monkey | ||
| SEPTERNA Aktie jetzt für 0€ handeln | |||||
| 03.03. | Septerna, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.02. | Septerna Stock Plunges 64% After Halting Phase 1 Trial Of SEP-786 | 2 | RTTNews | ||
| 18.02. | Septerna drops lead asset over bilirubin side effects 4 months after going public | 3 | FierceBiotech | ||
| 18.02. | JPMorgan maintains Septerna stock with $38 target despite trial pause | 3 | Investing.com | ||
| 18.02. | Septerna plunges as safety concerns force an end to early-stage trial | 2 | Seeking Alpha | ||
| 18.02. | Septerna shares plummet following clinical trial halt | 3 | Investing.com | ||
| 18.02. | Septerna halts trial for hypoparathyroidism drug | 1 | Investing.com | ||
| 18.02. | Septerna, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.01. | Septerna Appoints Gil Labrucherie As CFO, Pre-market Stock Drops | - | RTTNews | ||
| 06.01. | Septerna appoints new CFO to bolster financial strategy | 1 | Investing.com | ||
| 06.01. | Septerna, Inc.: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer | 120 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery... ► Artikel lesen | |
| 06.01. | Septerna, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.11.24 | Septerna, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 20.11.24 | Septerna, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.11.24 | Septerna, Inc.: Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 180 | GlobeNewswire (Europe) | Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule... ► Artikel lesen | |
| 19.11.24 | Septerna started by J.P. Morgan at overweight, GPCR platform cited | 3 | Seeking Alpha |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 1,174 | +0,86 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| XOMA ROYALTY | 20,800 | -1,89 % | Spotlight Stock Market: Market Notice 68/25 - Information regarding the rights issue from Xoma AB | ||
| ROCKET PHARMACEUTICALS | 6,626 | +1,59 % | Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress | CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 3,800 | +0,53 % | Vanda Pharmaceuticals Inc.: FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA | WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's... ► Artikel lesen | |
| ROIVANT SCIENCES | 9,304 | -3,67 % | Immunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 | Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 10,300 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial | After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 2,540 | 0,00 % | Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and More | ||
| ANNOVIS BIO | 1,440 | +1,55 % | Annovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE | MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 8,430 | 0,00 % | Forecasting The Future: 5 Analyst Projections For Arcus Biosciences | ||
| INMUNE BIO | 7,100 | 0,00 % | INmune Bio, Inc.: INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness | Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through... ► Artikel lesen | |
| TEMPUS AI | 53,50 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,170 | 0,00 % | Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock | ||
| SPRINGWORKS THERAPEUTICS | 44,990 | 0,00 % | EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme
Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
24.04.2025 /... ► Artikel lesen | |
| ARCELLX | 63,97 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 36,680 | 0,00 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen |
Das Unternehmen SEPTERNA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SEPTERNA INC finden Sie auf Wallstreet Online.
